Condition: Relapsed Non-Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma · Sponsor: Lyell Immunopharma, Inc.
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
This description comes directly from the study's public registry record.
Stephen Simko, MD · 000-000-0000 · clinicaltrials@lyell.com
Always discuss trial participation with your own doctor first.
| University of California-Irvine Medical Center | Irvine, California, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| University of California, Los Angeles (UCLA) Medical Center | Los Angeles, California, United States | Recruiting |
| Scripps Clinic | San Diego, California, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Medstar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Augusta University Medical Center | Augusta, Georgia, United States | Recruiting |
| Indiana Blood and Marrow Transplantation | Indianapolis, Indiana, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| University of Louisville Brown Cancer Center | Louisville, Kentucky, United States | Recruiting |
| Louisiana State University Health Sciences Center | Shreveport, Louisiana, United States | Recruiting |
| Corewell Health | Grand Rapids, Michigan, United States | Recruiting |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05826535